Analysts Set Compass Therapeutics, Inc. (NASDAQ:CMPX) Target Price at $11.38

Compass Therapeutics, Inc. (NASDAQ:CMPX) has received a consensus rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $13.38.

CMPX has been the topic of several research reports. Guggenheim reissued a “buy” rating and issued a $12.00 price target on shares of Compass Therapeutics in a research note on Wednesday, April 2nd. Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Leerink Partners upgraded Compass Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $4.00 to $6.00 in a research report on Wednesday, April 2nd. Wedbush reaffirmed an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Finally, D. Boral Capital reissued a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $1.46 on Wednesday. The business’s 50-day moving average is $2.76 and its two-hundred day moving average is $2.11. The company has a market capitalization of $201.89 million, a P/E ratio of -3.95 and a beta of 1.40. Compass Therapeutics has a fifty-two week low of $0.77 and a fifty-two week high of $4.08.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). Analysts forecast that Compass Therapeutics will post -0.36 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CMPX. Barclays PLC increased its stake in shares of Compass Therapeutics by 195.4% during the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after acquiring an additional 112,614 shares during the last quarter. SG Americas Securities LLC grew its holdings in Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after purchasing an additional 356,352 shares during the period. Geode Capital Management LLC increased its position in Compass Therapeutics by 0.8% during the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after purchasing an additional 19,095 shares during the last quarter. Bleakley Financial Group LLC raised its stake in Compass Therapeutics by 250.7% during the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock worth $58,000 after purchasing an additional 28,589 shares during the period. Finally, Intech Investment Management LLC boosted its holdings in shares of Compass Therapeutics by 218.7% in the 4th quarter. Intech Investment Management LLC now owns 51,924 shares of the company’s stock valued at $75,000 after purchasing an additional 35,632 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.